ArticleInternational journal of clinical and experimental medicine2015
Association of hOGG1 Ser326Cys polymorphism with susceptibility to hepatocellular carcinoma.
Article in International journal of clinical and experimental medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Shortened preoperative fasting for prevention of complications associated with laparoscopic cholecystectomy: a meta-analysis.The Journal of international medical research · 2017Pooled it
- Prickle4 Drives Microenvironmental Remodeling and Resistance to Parp Inhibition in IDH-Mutant Glioma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Review
- The hOGG1 Ser326Cys polymorphism and esophageal cancer risk: a meta-analysis of 1,875 cancer cases and 3,041 controls.Annals of translational medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSince, the relationship between hOGG1 Ser326Cys polymorphism and HCC was inconsistent in the recent literatures. The present meta-analysis based on previous studies was to obtain precise estimation on the issue.
methodsA computer search was carried out from PubMed, CBM and EMBASE databases. A total of nine case-control publications with 2583 HCC patients and 2271 controls were included in the meta-analysis. Pooled odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to evaluate the relationship of Ser326Cys polymorphism and HCC susceptibility. Z test was used to assess the significance of pooled OR. The fixed-effect model or random-effect model was employed according to heterogeneity.
resultsOverall, hOGG1 Ser326Cys polymorphism was in relation with increased risk for HCC under the following genetic models: GG versus CC: OR=2.51, 95% CI=1.67-3.78; GG versus CG + CC: OR=2.27, 95% CI=1.57-3.30; GG + CG versus CC: OR=1.13, 95% CI=1.03-1.24. The subgroup analysis by ethnicity suggested that high risk for HCC was observed in Asians with GG and GG + CG genotype (GG versus CC: OR=2.17, 95% CI=1.49-3.17; GG versus CG + CC: OR=1.96, 95% CI=1.41-2.73; GG + CG versus CC: OR=1.13, 95% CI=1.03-1.25). For subgroup analysis based on source of control, GG genotype of Ser326Cys was significantly associated with HCC risk in hospital-based (HB) controls (GG versus CC: OR=2.31, 95% CI=1.50-3.56; GG versus CG + CC: OR=2.17, 95% CI=1.44-3.28), as well as in population-based (PB) models (GG vs. CC: OR=2.80, 95% CI=1.16-6.77; GG versus CG + CC: OR=2.39, 95% CI=1.08-5.30).
conclusionsAccording to the results, hOGG1 Ser326Cys polymorphism was associated with increased risk of HCC.
Indexed as
Identifiers
26309550PMC4537974What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.